It is termed a specific therapy as it precisely targets the CD38 which can be overexpressed about the multiple myeloma cells. Daratumumab is from a class of medicines named CD38 monoclonal antibodies. DARZALEX® is provided being an intravenous (IV) infusion after dilution at 16 mg/kg of precise overall body weight2 https://adhdozempic.com/